PhRMA adds Genentech, Gilead Sciences to membership roster
With two new members, the Pharmaceutical Research and Manufacturers of America now represents all of the top 20 biopharmaceutical companies.
Pharma announced Thursday that Genentech, a member of the Roche Group, and Gilead Sciences have joined the association as members.
“PhRMA represents companies that are focused on making the promise of science a reality,” PhRMA president and CEO Stephen Ubl said. “I am proud to welcome two companies, Genentech and Gilead, who do just that into our membership. These companies also embody our commitment to proactively work with policymakers and stakeholders on common-sense policy solutions to evolve the healthcare system.”
Genentech and Gilead bolster PhRMA’s efforts to advance its proactive policy agenda, the organization said. PhRMA's policy focuses include more value-based contracts, delinking the supply chain from the list price, fixing the 340B Drug Pricing Program, and ensuring patients benefit from negotiated rebates at the pharmacy. PhRMA said the aim of its policy proposals are lower costs, improved patient affordability and an environment that fosters innovation.
“Collaboration among all stakeholders is essential to solving today’s most pressing healthcare challenges,” Roche Pharmaceuticals CEO and acting head of Genentech’s executive committee Bill Anderson, said. “We’re committed to finding solutions to complex problems, sustaining scientific innovation and ensuring people have access to the breakthrough medicines they need. As a member of PhRMA, we look forward to additional opportunities to engage in constructive dialogue that drives positive change for the healthcare system and lasting benefits for patients.”
Gilead’s chief patient officer and interim CEO Gregg Alton said, “We have a deep appreciation for the work PhRMA does as an organization to ensure that our industry can continue to pursue innovative new solutions and, importantly, to ensure patients have access to that innovation. We are looking forward to being a part of the important conversations and efforts that can help serve a greater number of people in need.”
Pharma announced Thursday that Genentech, a member of the Roche Group, and Gilead Sciences have joined the association as members.
“PhRMA represents companies that are focused on making the promise of science a reality,” PhRMA president and CEO Stephen Ubl said. “I am proud to welcome two companies, Genentech and Gilead, who do just that into our membership. These companies also embody our commitment to proactively work with policymakers and stakeholders on common-sense policy solutions to evolve the healthcare system.”
Genentech and Gilead bolster PhRMA’s efforts to advance its proactive policy agenda, the organization said. PhRMA's policy focuses include more value-based contracts, delinking the supply chain from the list price, fixing the 340B Drug Pricing Program, and ensuring patients benefit from negotiated rebates at the pharmacy. PhRMA said the aim of its policy proposals are lower costs, improved patient affordability and an environment that fosters innovation.
“Collaboration among all stakeholders is essential to solving today’s most pressing healthcare challenges,” Roche Pharmaceuticals CEO and acting head of Genentech’s executive committee Bill Anderson, said. “We’re committed to finding solutions to complex problems, sustaining scientific innovation and ensuring people have access to the breakthrough medicines they need. As a member of PhRMA, we look forward to additional opportunities to engage in constructive dialogue that drives positive change for the healthcare system and lasting benefits for patients.”
Gilead’s chief patient officer and interim CEO Gregg Alton said, “We have a deep appreciation for the work PhRMA does as an organization to ensure that our industry can continue to pursue innovative new solutions and, importantly, to ensure patients have access to that innovation. We are looking forward to being a part of the important conversations and efforts that can help serve a greater number of people in need.”